Jean-Christophe Brisset1, Benjamin A. Hoff1, Stefanie Galbn2, Benjamin Lemasson1, Alnawaz Rehemtulla2, Craig J. Galbn1, Brian D. Ross1
1Department of Radiology, University of Michigan, Ann Arbor, MI, United States; 2Department of Oncology, University of Michigan, Ann Arbor, MI, United States
Molecularly targeted therapies are seen as alternatives to chemotherapy in treating cancer. Although promising, typical volumetric based approaches for response assessment prove inadequate for targeted agents. This study aims to determine the effectiveness of DW-MRI at assessing response to an oral kinase inhibitor, Cabozantinib, after one week of treatment in a prostate bone metastasis model. We observed a significant increase in tumor ADC values following treatment by Cabozantinib, which correlated with the reduction in tumor growth rate. These results demonstrate the potential of quantitative ADC maps for assessing tumor response early following treatment completion.